Rictor is a novel target of p70 S6 kinase-1

Oncogene

Volumn 29, Issue 7, 2010, Pages 1003-1016

  Treins, C ^a,c   Warne, P H ^a   Magnuson, M A ^b   Pende, M ^c   Downward, J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSERM   (France)

Author keywords

Akt PKB; Amino acids; Feedback; MTORC2; Rictor; S6K

Indexed keywords

AMINO ACID; BINDING PROTEIN; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN 14 3 3; RAPAMYCIN INSENSITIVE COMPANION OF MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; S6 KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; VERTEBRATE;

14-3-3 PROTEINS; AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CELL LINE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RATS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; THREONINE; TRANSCRIPTION FACTORS;

MAMMALIA; VERTEBRATA;

EID: 77149163803     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.401     Document Type: Article

References (60)

1. Akcakanat A, Singh G, Hung MC, Meric-Bernstam F. (2007). Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun 362: 330-333.
2. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. (1996). Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 399: 333-338.
3. Aronova S, Wedaman K, Aronov PA, Fontes K, Ramos K, Hammock BD et al. (2008). Regulation of ceramide biosynthesis by TOR complex 2. Cell Metab 7: 148-158.
4. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen J, Li J et al. (2004). Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 101: 12130-12135.
5. Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F et al. (2008). Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 8: 411-424.
6. Bhaskar PT, Hay N. (2007). The two TORCs and Akt. Dev Cell 12: 487-502.
7. Cantin GT, Yi W, Lu B, Park SK, Xu T, Lee JD et al. (2008). Combining protein-based IMAC, peptide-based IMAC, and Mud-PIT for efficient phosphoproteomic analysis. J Proteome Res 7: 1346-1351.
8. Dai J, Jin WH, Sheng QH, Shieh CH, Wu JR, Zeng R. (2007). Protein phosphorylation and expression profiling by Yin-Yang multidimensional liquid chromatography (Yin-yang MDLC) mass spectro-metry. J Proteome Res 6: 250-262.
9. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R et al. (2008). Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31: 438-448.
10. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ et al. (2008). A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 105: 10762-10767.
11. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C et al. (2008). The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27: 1932-1943.
12. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA et al. (2006). mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865-1870.
13. Garcia-Martinez JM, Alessi DR. (2008). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416: 375-385.
14. Guertin DA, Sabatini DM. (2007). Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
15. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH et al. (2009). mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
16. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J et al. (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871.
17. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS et al. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
18. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S et al. (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
19. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3 K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
20. Hermeking H. (2003). The 14-3-3 cancer connection. Nat Rev Cancer 3: 931-943.
21. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. (2008). Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27: 1919-1931.
22. Inoki K, Li Y, Zhu T, Wu J, Guan KL. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657.
23. Inoki K, Ouyang H, Li Y, Guan KL. (2005). Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69: 79-100.
24. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY et al. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
25. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
26. Jones KT, Greer ER, Pearce D, Ashrafi K. (2009). Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol 7: e60.
27. Kamada Y, Fujioka Y, Suzuki NN, Inagaki F, Wullschleger S, Loewith R et al. (2005). Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol Cell Biol 25: 7239-7248.
28. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
29. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H et al. (2003). GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11: 895-904.
30. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence Jr JC. (2008). Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol Cell Biol 28: 61-70.
31. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D et al. (2002). Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468.
32. Ma XM, Blenis J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
33. Manning BD. (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167: 399-403.
34. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
35. Obenauer JC, Cantley LC, Yaffe MB. (2003). Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641.
36. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M et al. (2007). Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J405: 513-522.
37. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y et al. (2000). Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408: 994-997.
38. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J et al. (2004). S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124.
39. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
40. Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. (2002). Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6 K signaling. Genes Dev 16: 2627-2632.
41. Richardson CJ, Broenstrup M, Fingar DC, Julich K, Ballif BA, Gygi S et al. (2004). SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 14: 1540-1549.
42. Ruvinsky I, Meyuhas O. (2006). Ribosomal protein S6 phosphoryla-tion: from protein synthesis to cell size. Trends Biochem Sci 31: 342-348.
43. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L et al. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501.
44. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E et al. (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
45. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
46. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
47. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
48. Schalm SS, Blenis J. (2002). Identification of a conserved motif required for mTOR signaling. Curr Biol 12: 632-639.
49. Shah OJ, Wang Z, Hunter T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6 K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656.
50. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. (1998). Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17: 6649-6659.
51. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA. (2006). Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11: 583-589.
52. Soukas AA, Kane EA, Carr CE, Melo JA, Ruvkun G. (2009). Rictor/ TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev 23: 496-511.
53. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M et al. (2004). Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205.
54. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316-323.
55. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. (2008). Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 68: 7409-7418.
56. Wullschleger S, Loewith R, Hall MN. (2006). TOR signaling in growth and metabolism. Cell 124: 471-484.
57. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H et al. (1997). The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 91: 961-971.
58. Yang Q, Inoki K, Ikenoue T, Guan KL. (2006). Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20: 2820-2832.
59. Zanivan S, Gnad F, Wickstrom SA, Geiger T, Macek B, Cox J et al. (2008). Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7: 5314-5326.
60. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223-1233.